| |
Complete pairs
|
Decreasing
|
Unaltered
|
Increasing
|
P-value
|
|---|
|
ER
|
n = 30
|
2
|
25
|
3
|
0.68
|
|
PR
|
n = 30
|
3
|
21
|
6
|
0.19
|
|
HER2
|
n = 29
|
7
|
20
|
2
|
0.08
|
|
Cyclin D1 nuclear fraction
|
n = 30
|
4
|
19
|
7
|
0.12
|
|
Cyclin D1 nuclear intensity
|
n = 30
|
14
|
13
|
3
|
0.008*
|
|
Cyclin D1 cytoplasmic intensity
|
n = 30
|
10
|
14
|
6
|
0.48
|
|
p27 nuclear fraction
|
n = 33
|
2
|
22
|
9
|
0.03
|
|
p27 nuclear intensity
|
n = 33
|
9
|
18
|
6
|
0.35
|
|
p27 cytoplasmic intensity
|
n = 33
|
3
|
18
|
12
|
0.02
|
- P-values from Wilcoxon matched-pairs signed-ranks test.
- ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2.
- *Significant even after Bonferroni adjustment for multiple testing within the marker, P = 0.02.
